Cargando…

Reply: ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19

Detalles Bibliográficos
Autores principales:	Amat-Santos, Ignacio J., Santos-Martinez, Sandra, López-Otero, Diego, Delgado-Arana, Jose Raúl, San Román, J. Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier on behalf of the American College of Cardiology Foundation 2020
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572061/ https://www.ncbi.nlm.nih.gov/pubmed/33092743 http://dx.doi.org/10.1016/j.jacc.2020.08.064

Ejemplares similares

ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19
por: Wang, Yueying, et al.
Publicado: (2020)

Mechanisms by which angiotensin-receptor blockers increase ACE2 levels
por: Ferrario, Carlos M., et al.
Publicado: (2020)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes
por: Chae, Young Kwang, et al.
Publicado: (2013)

Reply to “Generic Statins and Angiotensin Receptor Blockers: Are They Really Useful in Ebola?”
por: Fedson, David S., et al.
Publicado: (2016)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

In reply— Association of Renin-Angiotensin System Blockers with Outcomes in Patients With COVID-19
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based antihypertensive therapies—reply
por: Albini, Adriana, et al.
Publicado: (2020)

Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction
por: Ko, Dennis, et al.
Publicado: (2019)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations
por: Wild, Philipp S., et al.
Publicado: (2020)

Should ACE Inhibitors and Angiotensin Receptor Blockers Be Withdrawn in the Current Setting of COVID-19 Infection?
por: Manga, Pravin
Publicado: (2020)

Robust ACE2 protein expression localizes to the motile cilia of the respiratory tract epithelia and is not increased by ACE inhibitors or angiotensin receptor blockers
por: Lee, Ivan T., et al.
Publicado: (2020)

Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people
por: Hippisley-Cox, Julia, et al.
Publicado: (2020)

Effect of ACE inhibitors and angiotensin receptor blockers on in-hospital mortality and length of stay in hospitalized COVID-19 patients
por: LaClair, Heather J., et al.
Publicado: (2021)

ACE Inhibitor/Angiotensin Receptor Blocker Use Patterns in Advanced CKD and Risk of Kidney Failure and Death
por: Arora, Nayan, et al.
Publicado: (2020)

Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study
por: Parit, Rahul, et al.
Publicado: (2021)

The presence of heart disease worsens prognosis in patients with COVID-19
por: San Román, J. Alberto, et al.
Publicado: (2020)

Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry
por: López-Otero, Diego, et al.
Publicado: (2021)

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020)

Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease
por: ElAbd, Rawan, et al.
Publicado: (2021)

Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients
por: Wang, Wenjun, et al.
Publicado: (2021)

RU28318, an Aldosterone Antagonist, in Combination with an ACE Inhibitor and Angiotensin Receptor Blocker Attenuates Cardiac Dysfunction in Diabetes
por: Benter, Ibrahim F., et al.
Publicado: (2013)

Associations between ACE-Inhibitors, Angiotensin Receptor Blockers, and Lean Body Mass in Community Dwelling Older Women
por: Bea, Jennifer W., et al.
Publicado: (2018)

Effect of angiotensin II blockers on the prognosis of COVID-19: a toxicological view
por: Shirazi, Farshad M., et al.
Publicado: (2020)

Kidney Function, ACE-Inhibitor/Angiotensin Receptor Blocker Use, and Survival Following Hospitalization for Heart Failure: A Cohort Study
por: Chiu, Michael H., et al.
Publicado: (2018)

Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Have No Significant Relationship With Postoperative Arthrofibrosis After Shoulder Arthroscopy
por: Bi, Andrew S., et al.
Publicado: (2023)

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic
por: Cure, Erkan, et al.
Publicado: (2020)

Impacto de las estatinas en los pacientes con COVID-19
por: Aparisi, Álvaro, et al.
Publicado: (2021)

Impact of statins in patients with COVID-19
por: Aparisi, Álvaro, et al.
Publicado: (2021)

Renin-angiotensin system inhibitors may have an advantage over calcium channel blockers in reducing proteinuria in gastric cancer patients receiving ramucirumab
por: Chiba, Takeshi, et al.
Publicado: (2022)

Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?
por: Trifirò, Gianluca, et al.
Publicado: (2020)

Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy
por: Malfertheiner, Peter, et al.
Publicado: (2018)

COVID-19 and ACE -inhibitors and angiotensin receptor blockers-: The need to differentiate between early infection and acute lung injury
por: GonzÃ¡lez-Rayas, JosÃ© Manuel, et al.
Publicado: (2020)

Association of outpatient ACE inhibitors and angiotensin receptor blockers and outcomes of acute respiratory illness: a retrospective cohort study
por: Jeffery, Molly Moore, et al.
Publicado: (2021)

Exome Sequencing Reveals Common and Rare Variants in F5 Associated With ACE Inhibitor and Angiotensin Receptor Blocker–Induced Angioedema
por: Maroteau, Cyrielle, et al.
Publicado: (2020)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis
por: Turgeon, Ricky D., et al.
Publicado: (2019)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Molecular Genetic Screening in Patients With ACE Inhibitor/Angiotensin Receptor Blocker-Induced Angioedema to Explore the Role of Hereditary Angioedema Genes
por: Mathey, Carina M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qnhqhqmng94n8uqj8t6fvdifrr